Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CVOT; VERTIS CV
- Sponsors Merck Sharp & Dohme Corp.
- 06 Oct 2023 Results of post hoc analysis assessing Effect of ertugliflozin on body weight and HbA1cby baseline BMI presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 06 Mar 2023 Results exploring bidirectional associations between hypoglycemia (HYPO) and CV outcomes,presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation
- 13 Feb 2023 Results of post hoc analysis exploring indices of hepatic steatosis/fibrosis and cardiorenal outcomes, published in the Diabetes, Obesity and Metabolism